

Notice of Allowability

Application No.

10/727,475

Applicant(s)

CASTRO ET AL.

Examiner

Art Unit

Binta M. Robinson

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment filed 12/6/04.
2. ☒ The allowed claim(s) is/are 14-17, 21 and 25-28 (now renumbered as claims 1-9).
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☒ Certified copies of the priority documents have been received in Application No. 09/857,882.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____ |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____ |

500

Art Unit: 1625

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Bob Gupta on 5/26/05.

The application has been amended as follows:

A. In claim 15, line 1, page 2, the phrase "use is made of an enzyme chosen" is deleted. The phrase "the enzyme is chosen" is added in its place.

B. In claim 16, line 1, page 2, the phrase "use is made of " is deleted. The phrase "the enzyme is" is added in its place.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Binta M. Robinson whose telephone number is (571) 272-0692. The examiner can normally be reached on M-F (9:30-6:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562.


A facsimile center has been established. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machine are (703)308-4242, (703)305-3592, and (703)305-3014.

Art Unit: 1625

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)-272-1600.

A handwritten signature in black ink, appearing to be 'BMR', written above the typed name and date.

BMR
May 26, 2005


Cecilia J. Tsang
Supervisory Patent Examiner
Technology Center 1600

Application of: Castro et al.

Docket No.: IVD 1072-3

Divisional of U.S. Application Serial No. 10/175,126

FOR: **ALKYL ESTERS OF 3-(3,4-DIHALOPHENYL)-2,6-DIOXOPIPERIDINE-3-PROPIONIC ACID OF USE AS INTERMEDIATES**

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EL676469550US

Date of Deposit: December 4, 2003

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:


Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Signature

ALKYL ESTERS OF 3-(3,4-DIHALOPHENYL)-2,6-DI-
OXOPIPERIDINE-3-PROPIONIC ACID OF USE AS INTERMEDIATES

The subject matter of the present invention
5 is a lower alkyl ester of 3-(3,4-dihalophenyl)-
2,6-dioxopiperidine-3-propionic acid. The invention
also relates to a process for the preparation of this
compound and to the use of said compound in preparing
the corresponding acid.
10 3-(3,4-Dichlorophenyl)-2,6-dioxopiperidine-
3-propionic acid is disclosed in Patent Application
WO 97/32852. According to this patent application,
3-(3,4-dichlorophenyl)-2,6-dioxopiperidine-3-propionic
acid can be reduced, for example by borane, to give
15 3-(3,4-dichlorophenyl)-3-(3-hydroxypropyl)piperidine.
The latter compound, disclosed in Patent Application
EP-A-673 928, is an intermediate of use in the
preparation of osanetant. Osanetant is a specific
antagonist of NK₃ receptors described, in particular, by
20 X. Emonds-Alt in Life Sci., 1995, 56 (1), 27-32.

The novel compound of formula:



in which:

- X represents a halogen, preferably a chlorine or fluorine atom;


- R₁ represents a linear C₁-C₄ alkyl, preferably a methyl;

has now been found.

The present invention relates very particularly to the compound of formula (I) in which $X = Cl$ and $R_1 = CH_3$.

10 The invention comprises the compound of
formula (I) in the racemic form and in the optically
pure form.


The compound of S configuration corresponding to the formula:



15 X

in which R_1 and X are as defined above for (I), is particularly preferred.


(According to the present invention, in order to prepare the compound of formula (I), an acid of
20 formula:



in which X is as defined for (I), is esterified. The compounds of formula (III) are disclosed in Patent Application WO 97/32852.

5 The esterification is carried out by conventional means well known to a person skilled in the art. For example, by the action of an alcohol in an acidic and anhydrous medium or alternatively by the action of thionyl chloride, to prepare the chloride of
10 the acid of formula (III) as an intermediate, and then by the action of an alcohol of formula R_1OH , in which R_1 is as defined above for (I).

 According to the process of the invention, the optical isomer of formula (II) can be prepared in
15 the optically pure form by a process characterized in that an enantioselective enzymatic hydrolysis of the compound of formula:



is carried out.

Thus, the racemic compound of formula (I) is hydrolyzed by an enzyme chosen from lipases, proteases or esterases, lipases or esterases being preferred.


Mention may be made, as nonlimiting examples, of lipases or esterases of *Candida cylindracea*, *Candida rugosa*, *Pseudomonas fluorescens*, *Humilica lanuginosa* or *Candida lipolytica*, α -chymotrypsin or pig liver esterase.

Preference is given to the esterase or the lipase of *Candida rugosa*, or of *Candida cylindracea*, separately or as a mixture.

These enzymes are used in the purified form or in the form of crude extracts. The enzymes may or may not be attached to a support.

The hydrolysis reaction is carried out according to the following reaction scheme:

Scheme 1



The enzymatic hydrolysis according to the invention is carried out in a medium comprising water and an organic solvent. The organic solvent can be nonpolar or moderately polar, such as a C₁-C₁₀ ether, a C₁-C₁₀ alkane, a C₁-C₁₀ tertiary alcohol, a C₁-C₁₀ ketone, a C₁-C₁₀ sulfoxide or furan, or, in some cases, a chlorinated solvent, such as dichloromethane, these solvents being used pure or as a mixture.

Preferably, use is made of a C₁-C₁₀ aliphatic ether, very particularly of methyl tert-butyl ether.

The water necessary for the hydrolysis can be dissolved in the reaction medium by a polar cosolvent or alternatively, preferably, the water constitutes a separate phase, the hydrolysis reaction then being carried out in a two-phase medium.

Thus, it is very particularly preferable to carry out the reaction in a two-phase medium composed of methyl tert-butyl ether (MTBE) and water. The MTBE/water ratio can vary from 1/99 to 99/1; a ratio of the order of 40/60 to 50/50, very particularly 44/56, is preferred.

The water used can be buffered or unbuffered and its pH can vary from 4 to 10 approximately; use is preferably made of water with a pH of the order of 5 to 8.

The concentration of diester in the reaction medium can vary in the proportions [lacuna] 1 to 500 g/l and preferably from 1 to 150 g/l, where the amount of enzyme varies in proportions from 0.0001 to 150 g/l and preferably from 1 to 50 g/l.


The temperature of the enzymatic hydrolysis reaction can vary between 0°C and +50°C and preferably between +16°C and +35°C.

The duration of the reaction is between 3 hours and 36 hours, generally in the region of 10 hours.

The chiral ester of formula (II) is isolated by extraction, after having precipitated and then filtered off the enzyme used.

According to the present invention, a compound of formula (II) can also be prepared by a

process consisting in carrying out a cyclization of the compound of formula:



in which R_1 and X are as defined above for (I).

5 The cyclization of the compound of formula (VI) is carried out either thermally or in the presence of a catalyst.

Thus, a thermal cyclization can be carried out between 170°C and 250°C, either in a molten medium
10 or in the presence of a solvent, for example an inert solvent, such as toluene, DMSO, sulfolane or tetralin. The thermal cyclization is preferably carried out in a molten medium at a temperature in the region of 200°C.

The cyclization can also be carried out in
15 the presence of a catalyst, such as an acid anhydride, for example acetic anhydride, phosphorus pentoxide, triflic anhydride, trifluoroacetic anhydride or methanesulfonic anhydride, or an acid, such as methanesulfonic acid or triflic acid, or a mixture of
20 an acid anhydride and of an acid.


It is preferable to use, as catalyst, methanesulfonic anhydride and methanesulfonic acid or triflic anhydride and triflic acid.

The cyclization reaction is carried out at a temperature of between 20°C and 130°C, preferably between 70°C and 120°C.

Catalytic cyclization, which makes it possible to retain the optical purity, is preferably used in carrying out the cyclization of the compound of formula (VI).

The compound of formula (II) is isolated from the medium by extraction using conditions known to a person skilled in the art.

The compound of formula (VI) is obtained by a process consisting in treating, by an enzyme, a compound of formula



in which R_1 and X_1 are as defined above for (I).


The preparation of a compound of formula (V) is disclosed in Patent Applications EP-A-673 928 and WO 97/32852.

To convert the racemic diester of formula (V) to the chiral hemiester of formula (VI), an enantioselective enzymatic hydrolysis is carried out while choosing conditions similar to those described above.

The chiral hemiester of formula (VI) is isolated from the medium either by selective extraction or by precipitation after acidification of the aqueous phase.

5 The compound of the formula (VI) is novel and constitutes a further aspect of the present invention.

According to a further aspect, the present invention relates to the use of a compound of formula (II) in the preparation of a compound of formula:



10


in which X is as defined above;

the hydrolysis of an ester of formula (II) being carried out under conditions which make it possible to retain the stereochemistry of the 3-carbon of the piperidinedione. Thus, use may be made of the action of an acid, for example the action of a carboxylic acid in the presence of an inorganic acid, preferably acetic acid in the presence of hydrochloric acid.

Thus, the present invention relates to a process for the preparation of a compound of formula (VII) by hydrolysis of an ester of formula (II).

20

According to another aspect, the present invention relates to the use of a compound of formula (II) in the preparation of a compound of formula:



5 The reduction of the compound of formula (II) to a compound of formula (VIII) can be carried out by the action of a reducing agent.

The reducing agents used are borane complexes, such as, for example, borane-tetrahydrofuran or borane-dimethyl sulfide, or alternatively a mixed alkaline hydride, such as lithium aluminum hydride or sodium bis(2-methoxyethoxy)aluminum hydride in solution in toluene (Red-Al®). These reductions take place without racemization; the preferred reducing agent is 15 the borane-tetrahydrofuran complex.


The reduction with borane is carried out in a solvent, preferably an aprotic solvent, such as tetrahydrofuran, at the reflux temperature of the solvent. The reduction is generally complete after 20 heating for 1 to 6 hours and the 3,3-disubstituted piperidine is isolated according to conventional methods, the excess borane first being destroyed with methanol. The free base can be isolated by evaporation

of the solvent and then the residue is taken up in water, acidification is carried out with hydrochloric acid, treatment is carried out with a base, preferably sodium hydroxide, and extraction is carried out with a solvent.

The free base of formula (VIII) can be converted to one of its salts according to well known techniques. The borane used for the reduction can be generated *in situ* according to conventional methods.


Thus, the present invention relates to a process for the preparation of a compound of formula (VIII) by reduction of a compound of formula (II).

Finally, according to another aspect, the present invention relates to the use of a compound of formula (VI) in the preparation of a compound of formula:



in which X is as defined above for (I), by reduction in the presence of an alkaline hydride, such as, for example, LiAlH_4 or LiAlH_3 in methanol.

A compound of formula:



is prepared by cyclization of the compound of formula (IX) under the conditions described above.

The compound of formula (IX) is novel and
5 forms part of the invention.

The compound of formula (X) is disclosed in International Patent Application WO 98/05640.

Thus, the present invention relates to a process for the preparation of a compound of formula
10 (IX) by reduction of a compound of formula (VI).

In the present description, the following abbreviations are used:

- DMSO: dimethyl sulfoxide
- MTBE: methyl *tert*-butyl ether
- 15 TFH: tetrahydrofuran
- iso ether: isopropyl ether
- AT: ambient temperature
- HPLC: high pressure liquid chromatography
- IR: infrared
- 20 NMR: nuclear magnetic resonance at 250 or 300 MHz
- δ : chemical shift, expressed in ppm
- s: singlet; d: doublet; d of d: doublet of doublet;

m: multiplet or unresolved peak.

The following examples illustrate the invention.

EXAMPLE 1

5 Methyl ester of 3-(3,4-dichlorophenyl)-2,6-dioxopiperidine-3-propionic acid

33 g of 3-(3,4-dichlorophenyl)-2,6-dioxopiperidine-3-propionic acid are placed in 300 ml of methanol and 1.5 g of H_2SO_4 in a 500 ml round-bottomed flask and then the mixture is heated at reflux for 45 minutes. The methanol is evaporated and then the residue is taken up in 300 ml of ether and stirred for 2 hours at AT. The precipitate formed is filtered off, rinsed with iso ether and then dried under vacuum at 15 40°C. 29.6 g of the expected ester are obtained. Yield 86%.

¹H NMR (DMSO) (solvent δ ¹H: 2.5 ppm):

δ : 11 (s, 1H); 7.26-7.65 (m, 3H); 3.51 (s, 3H); 2.06-2.51 (m, 8H)

20 EXAMPLE 2

Methyl ester of 3-(3,4-dichlorophenyl)-2,6-dioxopiperidine-3-propionic acid, (+) isomer, (Process 1)

5 g of *Candida cylindracea* L034 lipase (Biocatalysts), in suspension in 25 ml of 0.1M pH 7.0 phosphate buffer, are added to 1 g of methyl ester of racemic 3-(3,4-dichlorophenyl)-2,6-dioxopiperidine-3-

propionic acid in 20 ml of MTBE (50 g/l). The reaction mixture is thermostatically controlled at 40°C and stirred for 5 hours. The progress of the reaction is monitored by HPLC. After reacting for 5 hours, 48% of the starting material is hydrolyzed; the reaction is halted. 80 ml of MTBE are added to the reaction mixture and the latter is placed in ice, and 90 ml of acetone are incorporated in order to precipitate the enzyme. The precipitate is filtered off on a cellulose filter and then the organic solvents are evaporated. 2 equivalents of triethylamine are added to the remaining aqueous phase in order to bring the pH of the medium to 8.5. The non-hydrolyzed ester is extracted with 3 × 25 ml of dichloromethane. The dichloromethane phase is dried over anhydrous magnesium sulfate. After filtering and evaporating the dichloromethane to dryness (under vacuum), 500 mg of a yellow gum are isolated, corresponding to the expected compound (purity 96% by HPLC analysis). Extraction to an acidic pH is subsequently carried out. 25 ml of dichloromethane and 2 ml of 1N H₂SO₄ are added to the aqueous phase, with stirring and then extraction is carried out twice with 25 ml of dichloromethane. The organic phase is dried over anhydrous magnesium sulfate, filtered and evaporated to dryness under vacuum. 450 mg of white solid are obtained, analyzed by

HPLC: 100% of 3-(3,4-dichlorophenyl)-2,6-dioxopiperidine-3-propionic acid, (-) isomer.

NMR (DMSO) (solvent δ ^1H : 2.5 ppm):

3-(3,4-Dichlorophenyl)-2,6-dioxopiperidine-3-propionic
5 acid, (-) isomer:

δ : 12.10 (s, 1H); 11.0 (s, 1H); 7.66 (d, 1H); 7.55 (d, 1H); 7.28 (dd, 1H), 2.50-2.40 (m, 2H); 2.25-2.0 (m, 6H)

Expected compound:

δ : 11.0 (s, 1H); 7.66 (d, 1H); 7.55 (d, 1H); 7.28 (dd, 1H), 3.52 (s, 3H); 2.50-2.40 (m, 2H); 2.35-2.0 (m, 6H)

3-(3,4-Dichlorophenyl)-2,6-dioxopiperidine-3-propionic acid, (-) isomer.

$\alpha_D^{20} = -105$ (c = 0.25, methanol)

Expected compound:

15 $\alpha_D^{20} = +119$ (c = 0.25, methanol)

EXAMPLE 3

Methyl ester of 3-(3,4-dichlorophenyl)-2,6-dioxopiperidine-3-propionic acid, (+) isomer

(Process 2)

20 A)

Monomethyl ester of 4-cyano-4-(3,4-dichlorophenyl)-heptanedioic acid, (-) isomer

To 12 g of dimethyl ester of 4-cyano-4-(3,4-dichlorophenyl)heptanedioic acid are dissolved in 53 ml
25 of MTBE and 1 g of *Candida cylindracea* L034 lipase (Biocatalyst) are dissolved in 66 ml of 50 mM pH 7. phosphate buffer. The two solutions are mixed in a

500 ml three-necked round-bottomed flask. The reaction mixture is stirred vigorously, so as to create an emulsion. The temperature is set at 20°C. The reaction is halted after 5 hours. The progress of the reaction is monitored by HPLC.

The monomethyl ester is separated as follows: 240 ml of acetone are added to the reaction mixture and the medium is placed at 5°C for 2 hours in order to precipitate the lipase. After 2 hours, the precipitate is filtered on a cellulose filter. The organic solvents are evaporated from the liquid phase under reduced pressure. The resulting aqueous phase is basified to pH 9 (NaHCO_3) and extracted with toluene (240 ml). The toluene phase is evaporated to dryness. This results in a powder comprising 90% of starting dimethyl ester and 10% of expected monomethyl ester. The aqueous phase is acidified to pH 2.5 (1N HCl) and then extracted with CH_2Cl_2 (240 ml). After evaporating, the expected monomethyl ester is isolated in the form of a white powder: 7.8 g. Purity: 99%.

The monomethyl ester can also be separated in the following way:

At the end of the reaction, the mixture is basified at pH = 9 by addition of sodium hydroxide and then the aqueous phase and the organic phase are separated by settling. The organic phase is acidified up to pH = 2.5 by addition of HCl. A precipitate which

corresponds to the hemiester is formed and is recovered by filtration.

The hemiester can be purified by recrystallization from acetonitrile.

Percentage analysis:	C	H	N
Theory	52.34	4.32	4.06
Measured	52.24	4.33	4.10

5 Melting point: 110.2°C.

IR (nujol): 2238 cm^{-1} (nitrile); 1740 cm^{-1} (ester),
1693 cm^{-1} (carboxylic acid)

NMR (DMSO): δ

12.30 (s, 1H); 7.73 (d, 1H); 7.72 (d, 1H); 7.46 (dd,
10 1H); 3.51 (s, 3H); 2.40-2.28 (m, 4H); 2.35 (m, 1H);
2.25 (m, 1H); 2.07 (m, 1H); 1.95 (m, 1H)

^{13}C NMR (DMSO):

δ : 173.3, 172.2, 138.3, 132.5, 131.7, 131.6, 128.6,
127.2, 121.1, 52.0, 47.0, 34.8, 34.7, 30.5, 30.3

15 $\alpha_D^{20} = -1.2$ ($c = 1$, MeOH)

B)

Methyl ester of 3-(3,4-dichlorophenyl)-2,6-dioxo-
piperidine-3-propionic acid, (+ isomer)

1 g of the compound of stage A is introduced
20 into a sealable Pyrex tube. The tube is placed under
vacuum (water pump) and then sealed and brought to a
temperature of 250°C. After reacting for 5 hours, the
tube is cooled to ambient temperature and opened. The
reaction product is dissolved in 6 ml of THF. After

evaporating to dryness (under vacuum), the residue is dissolved in 50 ml of dichloromethane and the organic phase is washed with 3 x 50 ml of a 1M aqueous NaHCO_3 solution. After drying over anhydrous MgSO_4 and

5 evaporating the dichloromethane under vacuum, 700 mg of expected compound are isolated in the form of a yellow oil (purity 94%, HPLC). The product is recrystallized from isopropyl ether (yield: 70%).

Melting point: 105.5°C

10 $\alpha_D^{20} = +62$ (c = 1, methanol/THF; 188/12; v/v)

Methyl ester of 3-(3,4-dichlorophenyl)-2,6-dioxo-piperidine-3-propionic acid, (+ isomer)

This compound can also be prepared by heating in the presence of methanesulfonic acid anhydride
15 according to the process described below.

1 g of methanesulfonic acid anhydride and
60 mg of methanesulfonic acid (100%) are introduced into a 100 ml three-necked flask under a nitrogen stream. The mixture is heated until it melts. 1 g of
20 the compound of stage A is added to the reaction medium and the combined mixture is brought to 100°C. The reaction is monitored by thin layer chromatography (CH_2Cl_2 : MeOH, 95.5). After one hour, the reaction is halted. The medium is cooled to ambient temperature and
25 the anhydride is hydrolyzed by the addition of water. The reaction product is extracted with dichloromethane and purified by washing with a 1M aqueous NaHCO_3

solution. After drying over anhydrous MgSO_4 and evaporating the dichloromethane under vacuum, the glutaramide ester is isolated in the form of a yellow oil. The expected product crystallizes slowly while
5 exposed to the air: 0.85 g is obtained (HPLC analysis: chemical purity 98%). Melting point 105°C .
 $\alpha_D^{20} = +118^\circ\text{C}$ ($c = 0.25$, methanol)

The thermal cyclization reaction takes place partially with racemization in comparison with the
10 catalyzed cyclization reaction.

EXAMPLE 4

3-(3,4-Dichlorophenyl)-3-(3-hydroxypropyl)-piperidine fumarate

17.2 g of methyl ester of 3-(3,4-dichloro-
15 phenyl)-2,6-dioxopiperidine-3-propionic acid are dissolved in 50 ml of THF under nitrogen. 200 ml of 1M borane in THF are added over 10 minutes at 10°C . After heating at reflux for 2 hours, an additional 60 ml of 1M borane in THF are added and heating is maintained at
20 reflux for a further 1 hour. The excess borane is destroyed with methanol. After significant evolution of gas, the mixture is heated at reflux for 30 minutes and then the solvents are evaporated. The residue is taken up in 300 ml of water and 10 g of H_2SO_4 and then the
25 mixture is heated at reflux for 2 hours and left overnight at AT. 25 ml of concentrated sodium hydroxide solution are added and then extraction is carried out

(twice) with 80 ml of butanol. The organic phase is washed with 1000 ml of water and then concentrated, and the residue is taken up in 100 ml of isopropanol.

Heating is carried out at reflux, salification is

5 carried out by addition of 7 g of fumaric acid in 75 ml of isopropanol and the mixture is allowed to return to AT. The precipitate formed is filtered off and then dried under vacuum. 13.23 g of the expected compound are obtained.

10 The filtrates are concentrated and an additional 0.70 g of the expected compound is isolated. Overall yield: 81.5%.

EXAMPLE 5

3-(3,4-Dichlorophenyl)-2,6-dioxopiperidine-3-
15 propionic acid

Methyl ester of 3-(3,4-dichlorophenyl)-2,6-dioxopiperidine-3-propionic [lacuna], (+) isomer

This compound is prepared in Example 3, stage C.

20 B) 3-(3,4-Dichlorophenyl)-2,6-dioxopiperidine-3-propionic acid

0.668 g of the compound of the preceding stage, 2 ml of acetic acid and 0.10 ml of concentrated hydrochloric acid are introduced into a 100 ml three-
25 necked flask. The combined mixture is heated to 70°C. After 2 hours, the reaction product precipitates and the reaction is halted. After returning to ambient

temperature, 2 ml of water are added to the reaction medium. The reaction product is filtered off on a sintered glass filter, washed with water and then recrystallized from acetic acid. 0.47 g of the expected
5 compound is obtained. (Yield 70%).

$\alpha_D^{20} = +117$ ($c = 0.25$, methanol)

EXAMPLE 6

4-Cyano-4-(3,4-dichlorophenyl)-7-hydroxy-heptanoic acid

10 231 mg of LiBH_4 and 30 ml of MTBE are introduced under a nitrogen stream and then 429 μl of methanol, diluted in 30 ml of MTBE, are added dropwise. 1 g of compound prepared in Example 3, stage A, in solution in 80 ml of MTBE ether, is added to the
15 reaction medium and the combined mixture is heated at reflux. After three hours, the reaction medium is placed in ice and a 1N HCl solution is added. When there is no longer evolution of gas, the reaction product is extracted with dichloromethane. After drying
20 over anhydrous magnesium sulfate and evaporating the solvent under vacuum, the product is isolated in the form of a white gum.

The product is recrystallized from 6 ml of toluene and 600 mg of an expected compound are obtained
25 in the form of a white powder.

$\alpha_D^{20} = -10.7$ ($c = 1$, methanol).

NMR (DMSO) (solvent $\delta^1\text{H}$: 2.5 ppm):

δ : 12.30 (bs, 1H); 7.69 (d, 1H); 7.65 (d, 1H); 7.42
(dd, 1H); 4.5 (bs, 1H); 3.33 (t, 2H); 2.35-2.2 (m, 3H);
2.1-1.8 (m, 3H); 1.50-1.10 (m, 2H).

✕□△▢○■◆. △●✕▢■■ ▢■△▢◆✕ ▢▢●■▢
 ■▢◆◆△✕■✕▢▢ ▢
 ✕□△▢○■◆. △●✕▢■■ ▢▢○◆◆■◆ ▢▢●■▢
 ■▢◆◆△✕■✕▢▢ ▢

𐀀𐀁𐀂𐀃𐀄𐀅𐀆𐀇𐀈𐀉𐀊𐀋𐀌𐀍𐀎𐀏𐀐𐀑𐀒𐀓𐀔𐀕𐀖𐀗𐀘𐀙𐀚𐀛𐀜𐀝𐀞𐀟𐀠𐀡𐀢𐀣𐀤𐀥𐀦𐀧𐀨𐀩𐀪𐀫𐀬𐀭𐀮𐀯𐀰𐀱𐀲𐀳𐀴𐀵𐀶𐀷𐀸𐀹𐀺𐀻𐀼𐀽𐀾𐀿𐁀𐁁𐁂𐁃𐁄𐁅𐁆𐁇𐁈𐁉𐁊𐁋𐁌𐁍𐁎𐁏𐁐𐁑𐁒𐁓𐁔𐁕𐁖𐁗𐁘𐁙𐁚𐁛𐁜𐁝𐁞𐁟𐁠𐁡𐁢𐁣𐁤𐁥𐁦𐁧𐁨𐁩𐁪𐁫𐁬𐁭𐁮𐁯𐁰𐁱𐁲𐁳𐁴𐁵𐁶𐁷𐁸𐁹𐁺𐁻𐁼𐁽𐁾𐁿𐂀𐂁𐂂𐂃𐂄𐂅𐂆𐂇𐂈𐂉𐂊𐂋𐂌𐂍𐂎𐂏𐂐𐂑𐂒𐂓𐂔𐂕𐂖𐂗𐂘𐂙𐂚𐂛𐂜𐂝𐂞𐂟𐂠𐂡𐂢𐂣𐂤𐂥𐂦𐂧𐂨𐂩𐂪𐂫𐂬𐂭𐂮𐂯𐂰𐂱𐂲𐂳𐂴𐂵𐂶𐂷𐂸𐂹𐂺𐂻𐂼𐂽𐂾𐂿𐃀𐃁𐃂𐃃𐃄𐃅𐃆𐃇𐃈𐃉𐃊𐃋𐃌𐃍𐃎𐃏𐃐𐃑𐃒𐃓𐃔𐃕𐃖𐃗𐃘𐃙𐃚𐃛𐃜𐃝𐃞𐃟𐃠𐃡𐃢𐃣𐃤𐃥𐃦𐃧𐃨𐃩𐃪𐃫𐃬𐃭𐃮𐃯𐃰𐃱𐃲𐃳𐃴𐃵𐃶𐃷𐃸𐃹𐃺𐃻𐃼𐃽𐃾𐃿𐄀𐄁𐄂𐄃𐄄𐄅𐄆𐄇𐄈𐄉𐄊𐄋𐄌𐄍𐄎𐄏𐄐𐄑𐄒𐄓𐄔𐄕𐄖𐄗𐄘𐄙𐄚𐄛𐄜𐄝𐄞𐄟𐄠𐄡𐄢𐄣𐄤𐄥𐄦𐄧𐄨𐄩𐄪𐄫𐄬𐄭𐄮𐄯𐄰𐄱𐄲𐄳𐄴𐄵𐄶𐄷𐄸𐄹𐄺𐄻𐄼𐄽𐄾𐄿𐅀𐅁𐅂𐅃𐅄𐅅𐅆𐅇𐅈𐅉𐅊𐅋𐅌𐅍𐅎𐅏𐅐𐅑𐅒𐅓𐅔𐅕𐅖𐅗𐅘𐅙𐅚𐅛𐅜𐅝𐅞𐅟𐅠𐅡𐅢𐅣𐅤𐅥𐅦𐅧𐅨𐅩𐅪𐅫𐅬𐅭𐅮𐅯𐅰𐅱𐅲𐅳𐅴𐅵𐅶𐅷𐅸𐅹𐅺𐅻𐅼𐅽𐅾𐅿𐆀𐆁𐆂𐆃𐆄𐆅𐆆𐆇𐆈𐆉𐆊𐆋𐆌𐆍𐆎𐆏𐆐𐆑𐆒𐆓𐆔𐆕𐆖𐆗𐆘𐆙𐆚𐆛𐆜𐆝𐆞𐆟𐆠𐆡𐆢𐆣𐆤𐆥𐆦𐆧𐆨𐆩𐆪𐆫𐆬𐆭𐆮𐆯𐆰𐆱𐆲𐆳𐆴𐆵𐆶𐆷𐆸𐆹𐆺𐆻𐆼𐆽𐆾𐆿𐇀𐇁𐇂𐇃𐇄𐇅𐇆𐇇𐇈𐇉𐇊𐇋𐇌𐇍𐇎𐇏𐇐𐇑𐇒𐇓𐇔𐇕𐇖𐇗𐇘𐇙𐇚𐇛𐇜𐇝𐇞𐇟𐇠𐇡𐇢𐇣𐇤𐇥𐇦𐇧𐇨𐇩𐇪𐇫𐇬𐇭𐇮𐇯𐇰𐇱𐇲𐇳𐇴𐇵𐇶𐇷𐇸𐇹𐇺𐇻𐇼𐇽𐇾𐇿𐈀𐈁𐈂𐈃𐈄𐈅𐈆𐈇𐈈𐈉𐈊𐈋𐈌𐈍𐈎𐈏𐈐𐈑𐈒𐈓𐈔𐈕𐈖𐈗𐈘𐈙𐈚𐈛𐈜𐈝𐈞𐈟𐈠𐈡𐈢𐈣𐈤𐈥𐈦𐈧𐈨𐈩𐈪𐈫𐈬𐈭𐈮𐈯𐈰𐈱𐈲𐈳𐈴𐈵𐈶𐈷𐈸𐈹𐈺𐈻𐈼𐈽𐈾𐈿𐉀𐉁𐉂𐉃𐉄𐉅𐉆𐉇𐉈𐉉𐉊𐉋𐉌𐉍𐉎𐉏𐉐𐉑𐉒𐉓𐉔𐉕𐉖𐉗𐉘𐉙𐉚𐉛𐉜𐉝𐉞𐉟𐉠𐉡𐉢𐉣𐉤𐉥𐉦𐉧𐉨𐉩𐉪𐉫𐉬𐉭𐉮𐉯𐉰𐉱𐉲𐉳𐉴𐉵𐉶𐉷𐉸𐉹𐉺𐉻𐉼𐉽𐉾𐉿𐊀𐊁𐊂𐊃𐊄𐊅𐊆𐊇𐊈𐊉𐊊𐊋𐊌𐊍𐊎𐊏𐊐𐊑𐊒𐊓𐊔𐊕𐊖𐊗𐊘𐊙𐊚𐊛𐊜𐊝𐊞𐊟𐊠𐊡𐊢𐊣𐊤𐊥𐊦𐊧𐊨𐊩𐊪𐊫𐊬𐊭𐊮𐊯𐊰𐊱𐊲𐊳𐊴𐊵𐊶𐊷𐊸𐊹𐊺𐊻𐊼𐊽𐊾𐊿𐋀𐋁𐋂𐋃𐋄𐋅𐋆𐋇𐋈𐋉𐋊𐋋𐋌𐋍𐋎𐋏𐋐𐋑𐋒𐋓𐋔𐋕𐋖𐋗𐋘𐋙𐋚𐋛𐋜𐋝𐋞𐋟𐋠𐋡𐋢𐋣𐋤𐋥𐋦𐋧𐋨𐋩𐋪𐋫𐋬𐋭𐋮𐋯𐋰𐋱𐋲𐋳𐋴𐋵𐋶𐋷𐋸𐋹𐋺𐋻𐋼𐋽𐋾𐋿𐌀𐌁𐌂𐌃𐌄𐌅𐌆𐌇𐌈𐌉𐌊𐌋𐌌𐌍𐌎𐌏𐌐𐌑𐌒𐌓𐌔𐌕𐌖𐌗𐌘𐌙𐌚𐌛𐌜𐌝𐌞𐌟𐌠𐌡𐌢𐌣𐌤𐌥𐌦𐌧𐌨𐌩𐌪𐌫𐌬𐌭𐌮𐌯𐌰𐌱𐌲𐌳𐌴𐌵𐌶𐌷𐌸𐌹𐌺𐌻𐌼𐌽𐌾𐌿𐍀𐍁𐍂𐍃𐍄𐍅𐍆𐍇𐍈𐍉𐍊𐍋𐍌𐍍𐍎𐍏𐍐𐍑𐍒𐍓𐍔𐍕𐍖𐍗𐍘𐍙𐍚𐍛𐍜𐍝𐍞𐍟𐍠𐍡𐍢𐍣𐍤𐍥𐍦𐍧𐍨𐍩𐍪𐍫𐍬𐍭𐍮𐍯𐍰𐍱𐍲𐍳𐍴𐍵𐍶𐍷𐍸𐍹𐍺𐍻𐍼𐍽𐍾𐍿𐎀𐎁𐎂𐎃𐎄𐎅𐎆𐎇𐎈𐎉𐎊𐎋𐎌𐎍𐎎𐎏𐎐𐎑𐎒𐎓𐎔𐎕𐎖𐎗𐎘𐎙𐎚𐎛𐎜𐎝𐎞𐎟𐎠𐎡𐎢𐎣𐎤𐎥𐎦𐎧𐎨𐎩𐎪𐎫𐎬𐎭𐎮𐎯𐎰𐎱𐎲𐎳𐎴𐎵𐎶𐎷𐎸𐎹𐎺𐎻𐎼𐎽𐎾𐎿𐏀𐏁𐏂𐏃𐏄𐏅𐏆𐏇𐏈𐏉𐏊𐏋𐏌𐏍𐏎𐏏𐏐𐏑𐏒𐏓𐏔𐏕𐏖𐏗𐏘𐏙𐏚𐏛𐏜𐏝𐏞𐏟𐏠𐏡𐏢𐏣𐏤𐏥𐏦𐏧𐏨𐏩𐏪𐏫𐏬𐏭𐏮𐏯𐏰𐏱𐏲𐏳𐏴𐏵𐏶𐏷𐏸𐏹𐏺𐏻𐏼𐏽


📄📄💻👍😞👎💧💧

📄🖱️💻👍😞👉💧💧

📄🔌💻👍😞✌️💧💧

[illegible]

The chemical structure shows a central cyclohexane ring. Attached to one carbon of the ring are four substituents: a carboxymethyl group (CH_2COOH), a hydroxymethyl group (CH_2OH), a 2-alkoxyethyl group ($\text{CH}_2\text{CH}_2\text{OR}$), and two 'X' substituents. The 2-alkoxyethyl group is shown with a wedge bond to the ring and a dashed bond to the oxygen atom. The 'X' substituents are also shown with wedge and dash bonds to the ring.




[illegible]

[illegible]


□

=====



Chemical structure diagram showing a substituted cyclohexane derivative. The central cyclohexane ring is substituted at one carbon with a carboxylic acid group (-COOH) and a methylene group (-CH₂-). This methylene group is further substituted with a hydroxyl group (-OH) and a methylene group (-CH₂-). This second methylene group is further substituted with a carbonyl group (-C=O) and a methylene group (-CH₂-). This third methylene group is further substituted with an oxygen atom (-O-) and a methyl group (-CH₃). The cyclohexane ring is also substituted at the adjacent carbon with two 'X' groups.

























































[illegible]













[illegible]









□×■_၆ **ဝိ□■_၁** **📖**




■□□○☞●✕✕ℓ⊆ ∂□■⊆♦ 🖨






















✕•□●☉◆♁♂ □✕■♂ ♦△♦◆♁○

[illegible]





























































































၁။ မြေအောက်ရေဝန်ခံမှု၊ အောက်မြေအောက်ရေဝန်ခံမှု၊ အောက်မြေအောက်ရေဝန်ခံမှု



ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁



ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁

ကုမ္ပဏီ အမှတ် ၁


ကုမ္ပဏီ အမှတ် ၁



ကုမ္ပဏီ အမှတ် ၁








☐✕☐₉ **☐☐♠₇** • 



☐✕■↳ ⓪☐■Ⓡ♦ 📖





















■□□○◎●✕✕ㄴㄴ ㄱ□■ㄴ,

✕◻●☞◆♣♠ ◻✕■♥ ◆◻▲♦◆♣○ ◻









































Chemical structure diagram showing a substituted cyclohexylamine derivative. The structure consists of a cyclohexylamine ring connected to a cyclohexene ring. The cyclohexene ring has two substituents labeled 'X'. The cyclohexylamine ring is connected to a chain consisting of a methylene group, a bracketed methylene group with a subscript '0-2', another methylene group, and a terminal hydroxyl group.









































၁။ နမူနာပေးသော နမူနာများကို အောက်ပါအတိုင်း ဖော်ပြထားပါသည်။



နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

နမူနာပေးသော နမူနာများ

Chemical structure of a substituted cyclohexane derivative. The cyclohexane ring is substituted with an NH group, a carbonyl group (C=O), a hydroxymethyl group (-CH₂OH), and a 2,4-dihalo-6-(2-oxocyclohexyl)phenyl group. The phenyl ring has two halogen atoms (X) at the 2 and 4 positions. The cyclohexane ring is numbered 1 to 6, starting from the carbon attached to the phenyl group.

